Dirix Piet, Vingerhoedt Sofie, Joniau Steven, Van Cleynenbreugel Ben, Haustermans Karin
Department of Radiation Oncology, Leuvens Kankerinstituut (LKI), University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
Department of Radiation Oncology, Iridium Cancer Network, GZA St Augustinus Hospital, Oosterveldlaan 24, Wilrijk (Antwerp), Antwerp, Belgium.
Support Care Cancer. 2016 Jan;24(1):181-186. doi: 10.1007/s00520-015-2765-y. Epub 2015 May 16.
The aim of this study was to evaluate hematuria-free survival as well as acute and late toxicity after hypofractionated palliative radiotherapy for bladder cancer.
Between September 2004 and January 2013, 44 patients with biopsy-proven urothelial carcinoma of the bladder were irradiated according to a palliative schedule to a total dose of 34.5 Gy in six fractions of 5.75 Gy given once a week.
After a mean follow-up of 10 months, 91% of patients were still hematuria free, with a mean hematuria-free survival of 13 months. Severe (≥ grade 3) acute and late urinary toxicity was observed in 9 and 19% of patients, respectively.
This hypofractionated radiotherapy schedule appears to result in acceptable toxicity and manages successful and long-term palliation of hematuria in most patients.
本研究旨在评估膀胱癌大分割姑息性放疗后的无血尿生存期以及急性和晚期毒性。
2004年9月至2013年1月期间，44例经活检证实为膀胱尿路上皮癌的患者按照姑息性放疗方案接受治疗，总剂量34.5 Gy，分6次给予，每次5.75 Gy，每周1次。
平均随访10个月后，91%的患者仍无血尿，平均无血尿生存期为13个月。分别有9%和19%的患者出现严重（≥3级）急性和晚期泌尿系统毒性。
这种大分割放疗方案似乎能产生可接受的毒性，并在大多数患者中成功实现长期的血尿姑息治疗。
